Literature DB >> 20925555

Incentives for drug development—the curious case of colchicine.

Janet Woodcock, Sarah Okada.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20925555     DOI： 10.1056/NEJMc1007963

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Good Intentions, Unintended Consequences, and Unrealized Benefits.

Authors:  John D FitzGerald
Journal:  J Gen Intern Med       Date:  2015-11       Impact factor: 5.128

2.  Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population.

Authors:  Aaron S Kesselheim; Jessica M Franklin; Seoyoung C Kim; John D Seeger; Daniel H Solomon
Journal:  J Gen Intern Med       Date:  2015-04-09       Impact factor: 5.128

3.  Diagnosis and Treatment of Acute Gout at a University Hospital Emergency Department.

Authors:  Naomi Schlesinger; Diane C Radvanski; Tina C Young; Jonathan V McCoy; Robert Eisenstein; Dirk F Moore
Journal:  Open Rheumatol J       Date:  2015-06-12

Review 4.  Recent trends in specialty pharma business model.

Authors:  Mannching Sherry Ku
Journal:  J Food Drug Anal       Date:  2015-05-21       Impact factor: 6.157
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.